Cytokinetics presents new data on the safety and long-term use of Aficamten at the European Society of Cardiology Congress 2024

Posted on September 1, 2024 by Vaseline

Cytokinetics presents new data on the safety and long-term use of Aficamten at the European Society of Cardiology Congress 2024

Data from integrated safety analysis of three clinical studies
Aficamten’s Enhanced Robust Safety Profile

Analysis of FOREST-HCM shows successful
Withdrawal of standard care medicines
in patients with obstructive HCM treated with Aficamten